Plain-English translation of NCT07019922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether elsunersen, a new medication, can help control seizures in young children who have a rare genetic form of epilepsy caused by a change in the SCN2A gene. The study will measure how well the medication reduces seizures and how safe it is for children who started having seizures very early in life. Researchers want to understand if this treatment can make a real difference for children living with this condition.
Early-onset SCN2A-related epilepsy is a rare genetic condition that causes frequent, difficult-to-control seizures starting in infancy. Right now, there are limited treatment options available, so this trial is testing whether this medication can offer a new way to help reduce seizures and improve outcomes for affected children.
You likely qualify if…
You likely don't qualify if…
Your child will receive the medication elsunersen as part of this open-label trial, meaning you and your medical team will know your child is receiving the treatment. The study involves multiple visits at specialized medical centers where your child's seizure activity and overall health will be closely monitored. You'll work with the research team to track how your child responds to the medication and report any side effects or changes you notice.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States